Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449156) titled 'A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris' on Feb. 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Care Provider).
Primary Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
Condition:
Acne Vulgaris
Intervention:
Drug: HB0043
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 27, 2026
Target Sample Size: 21
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study...